BPBibek Poudel

Bibek Poudel

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Bibek Poudel has a total of 34 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Top Cited Papers
    Open Access

    Cell-Specific Inducible Human APOL1 Risk Variant Expression in Mice Causes Hypertension and Renal Damage

    by Fang Li, Bibek Poudel, Magaiver Andrade-Silva, Junnan Wu, Archana Raman, Elisa Cruz-Morales, Joseph Wahba, Allison Vassalotti, Chenyu Li, Amin Abedini, et al.

    BACKGROUND: Black people bear a disproportionate burden of hypertension and hypertension-attributed chronic kidney disease. A role of apolipoprotein L1 ( APOL1 ) risk variants (RVs; G1 and G2) in these conditions has been proposed, but genetic and observational studies have shown inconsistent results. METHODS: Here, we investigated the causal role of APOL1 RVs using patient samples, transgenic animal models, and in vitro primary cellular experiments. RESULTS: In the human kidney, APOL1 was highly expressed by glomerular podocytes and endothelial cells. Mice with podocyte-specific expression of the APOL1 RV (G2 APOL1 ), but not those with the reference allele (G0), developed severe secondary hypertension after albuminuria and kidney disease. Mice expressing endothelium-specific G2 APOL1 RVs developed mild hypertension with aging, which was exacerbated after unilateral nephrectomy and subsequent high-salt diet feeding. This condition was associated with a slight alteration in kidney function. In vitro and in vivo experiments demonstrated that the APOL1 RV activates the cytosolic nucleotide sensor STING (stimulator of interferon genes), leading to increased production of endothelin 1. Notably, mice with endothelium-specific STING knockout or those treated with an endothelin inhibitor showed protection from G2 APOL1 RV–mediated hypertension. CONCLUSIONS: These findings indicate a role of G2 APOL1 in hypertension development through STING and endothelin 1 activation, offering new precision therapeutics for addressing hypertension in Black people carrying APOL1 RVs.


  • Open Access

    Single-cell transcriptomics and chromatin accessibility profiling elucidate the kidney-protective mechanism of mineralocorticoid receptor antagonists

    by Amin Abedini, Andrea Sánchez-Navaro, Junnan Wu, Konstantin A. Klötzer, Ziyuan Ma, Bibek Poudel, Tomohito Doke, Michael S. Balzer, Julia Frederick, Hana Cernecka, et al.

    Mineralocorticoid excess commonly leads to hypertension (HTN) and kidney disease. In our study, we used single-cell expression and chromatin accessibility tools to characterize the mineralocorticoid target genes and cell types. We demonstrated that mineralocorticoid effects were established through open chromatin and target gene expression, primarily in principal and connecting tubule cells and, to a lesser extent, in segments of the distal convoluted tubule cells. We examined the kidney-protective effects of steroidal and nonsteroidal mineralocorticoid antagonists (MRAs), as well as of amiloride, an epithelial sodium channel inhibitor, in a rat model of deoxycorticosterone acetate, unilateral nephrectomy, and high-salt consumption–induced HTN and cardiorenal damage. All antihypertensive therapies protected against cardiorenal damage. However, finerenone was particularly effective in reducing albuminuria and improving gene expression changes in podocytes and proximal tubule cells, even with an equivalent reduction in blood pressure. We noted a strong correlation between the accumulation of injured/profibrotic tubule cells expressing secreted posphoprotein 1 (Spp1), Il34, and platelet-derived growth factor subunit b (Pdgfb) and the degree of fibrosis in rat kidneys. This gene signature also showed a potential for classifying human kidney samples. Our multiomics approach provides fresh insights into the possible mechanisms underlying HTN-associated kidney disease, the target cell types, the protective effects of steroidal and nonsteroidal MRAs, and amiloride.


  • Chronic treatment with IL-25 increases renal M2 macrophages and reduces renal injury in obese Dahl salt-sensitive rats during the prepubescent stage

    by Bibek Poudel, Ubong S. Ekperikpe, Sautan Mandal, Gregory E. Wilson, Corbin A. Shields, Denise C. Cornelius, Jan M. Williams

    For the past few decades, immune cells and inflammatory cytokines have been demonstrated to play an important role in the development of renal disease. The present study provides strong evidence that interleukin-25 slows the early progression of renal injury in obese Dahl salt-sensitive rats before puberty by increasing systemic anti-inflammatory cytokines and renal M2a macrophages.


  • Open Access

    IL‐25 reduces early progression of renal injury in obese Dahl salt‐sensitive rats via inducing renal M2a‐macrophages and suppressing M1‐macrophages

    by Bibek Poudel, Corbin Shields, Ubong Ekperikpe, Andrea Brown, Denise Cornelius, Jan Williams

    Recently, we reported that the early progression of proteinuria in the obese Dahl salt‐sensitive (SS LepR mutant) strain was associated with increased renal macrophage infiltration in the absence of hyperglycemia and elevations in arterial pressure. Macrophages (CD68 + ) can be divided into two distinct phenotypes: M1‐macrophages (pro‐inflammatory; CD68 + /iNOS + ), and M2‐macrophages (anti‐inflammatory; CD68 + /CD163 + ). M1‐macrophages induce renal inflammation and fibrosis, whereas M2‐macrophages reduce renal inflammation and fibrosis. Moreover, previous studies have demonstrated that interlukin‐25 (IL‐25) converts resting macrophages and M1‐macrophages into M2‐macrophagess. Therefore, the objective of the current study was to examine whether treatment with IL‐25 would reduce the early progression of renal injury in SS LepR mutant rats by increasing renal M2‐macrophages. We also investigated the impact of IL‐25 on M2‐macrophage subtypes: M2a (wound healing/anti‐inflammatory; CD68 + /CD163 + /TLR1 ‐ ), M2b (immune mediated/pro‐inflammatory; CD68 + /iNOS ‐ /CD86 + ), M2c (Regulatory/anti‐inflammatory; CD68+/CD163+/TLR1 + ), and M2d (tumor associated macrophage/pro‐angiogenic; CD68 + /VEGF + ). Four week‐old SS WT and SS LepR mutant rats were treated with either vehicle (PBS) or IL‐25 (1µg/day, i.p., every other day) for 4 weeks. While the administration of IL‐25 did not change total renal macrophage infiltration in both SS WT and SS LepR mutant rats, IL‐25 increased M2a‐macrophages by >50% and reduced M1‐macrophage by 60% in the kidneys of SS LepR mutant rats. Interestingly, IL‐25 significantly increased the insulin sensitivity without changing plasma glucose, triglyceride and total cholesterol levels in SS LepR mutant rats. IL‐25 administration had no effect on the progression of proteinuria or renal histopathology in SS WT rats. However, in the SS LepR mutant strain, proteinuria was markedly reduced during the first 2 weeks of treatment (105±13 vs. 295±45 mg/day, respectively), which was further consistent after 4 weeks of treatment (314±57 vs. 467±55 mg/day, respectively). The kidneys from SS LepR mutant rats displayed glomerular injury with increased mesangial expansion and renal fibrosis versus SS WT rats. Chronic treatment with IL‐25 significantly decreased glomerular injury and renal fibrosis in the SS LepR mutant strain. Overall, these data indicate that IL‐25 reduces the early progression of renal injury in SS LepR mutant rats by inducing M2a‐macrophages and suppressing M1‐macrophages. Therefore, IL‐25 may be considered a therapeutic target for renal disease associated with obesity.